Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune Myelopathy
Autoimmune myelopathies are immune-mediated disorders of the spinal cord that can cause significant neurologic disability. Discoveries of antibodies targeting aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) have facilitated the diagnosis of autoimmune myelopathies that were...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.912050/full |
| _version_ | 1811339911401308160 |
|---|---|
| author | Samir Alkabie Adrian Budhram Adrian Budhram |
| author_facet | Samir Alkabie Adrian Budhram Adrian Budhram |
| author_sort | Samir Alkabie |
| collection | DOAJ |
| description | Autoimmune myelopathies are immune-mediated disorders of the spinal cord that can cause significant neurologic disability. Discoveries of antibodies targeting aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) have facilitated the diagnosis of autoimmune myelopathies that were previously considered to be atypical presentations of multiple sclerosis (MS) or idiopathic, and represent major advancements in the field of autoimmune neurology. The detection of these antibodies can substantially impact patient diagnosis and management, and increasing awareness of this has led to a dramatic increase in testing for these antibodies among patients with suspected autoimmune myelopathy. In this review we discuss test methodologies used to detect these antibodies, the role of serum vs. cerebrospinal fluid testing, and the value of antibody titers when interpreting results, with the aim of helping laboratorians and clinicians navigate this testing when ordered as part of the diagnostic evaluation for suspected autoimmune myelopathy. |
| first_indexed | 2024-04-13T18:33:27Z |
| format | Article |
| id | doaj.art-a4b206ad844e4812a0bf55681ccb2e31 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-13T18:33:27Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-a4b206ad844e4812a0bf55681ccb2e312022-12-22T02:34:59ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-05-011310.3389/fneur.2022.912050912050Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune MyelopathySamir Alkabie0Adrian Budhram1Adrian Budhram2Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, London, ON, CanadaDepartment of Clinical Neurological Sciences, London Health Sciences Centre, Western University, London, ON, CanadaDeparment of Pathology and Laboratory Medicine, London Health Sciences Centre, Western University, London, ON, CanadaAutoimmune myelopathies are immune-mediated disorders of the spinal cord that can cause significant neurologic disability. Discoveries of antibodies targeting aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) have facilitated the diagnosis of autoimmune myelopathies that were previously considered to be atypical presentations of multiple sclerosis (MS) or idiopathic, and represent major advancements in the field of autoimmune neurology. The detection of these antibodies can substantially impact patient diagnosis and management, and increasing awareness of this has led to a dramatic increase in testing for these antibodies among patients with suspected autoimmune myelopathy. In this review we discuss test methodologies used to detect these antibodies, the role of serum vs. cerebrospinal fluid testing, and the value of antibody titers when interpreting results, with the aim of helping laboratorians and clinicians navigate this testing when ordered as part of the diagnostic evaluation for suspected autoimmune myelopathy.https://www.frontiersin.org/articles/10.3389/fneur.2022.912050/fullmyelitisautoimmune neurologyneuroimmunologyneuroinflammationautoantibody |
| spellingShingle | Samir Alkabie Adrian Budhram Adrian Budhram Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune Myelopathy Frontiers in Neurology myelitis autoimmune neurology neuroimmunology neuroinflammation autoantibody |
| title | Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune Myelopathy |
| title_full | Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune Myelopathy |
| title_fullStr | Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune Myelopathy |
| title_full_unstemmed | Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune Myelopathy |
| title_short | Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune Myelopathy |
| title_sort | testing for antibodies against aquaporin 4 and myelin oligodendrocyte glycoprotein in the diagnosis of patients with suspected autoimmune myelopathy |
| topic | myelitis autoimmune neurology neuroimmunology neuroinflammation autoantibody |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.912050/full |
| work_keys_str_mv | AT samiralkabie testingforantibodiesagainstaquaporin4andmyelinoligodendrocyteglycoproteininthediagnosisofpatientswithsuspectedautoimmunemyelopathy AT adrianbudhram testingforantibodiesagainstaquaporin4andmyelinoligodendrocyteglycoproteininthediagnosisofpatientswithsuspectedautoimmunemyelopathy AT adrianbudhram testingforantibodiesagainstaquaporin4andmyelinoligodendrocyteglycoproteininthediagnosisofpatientswithsuspectedautoimmunemyelopathy |